Immuron Limited (IMRN): Price and Financial Metrics

Immuron Limited (IMRN): $1.80

0.05 (+2.97%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add IMRN to Watchlist
Sign Up

IMRN Price/Volume Stats

Current price $1.80 52-week high $3.21
Prev. close $1.75 52-week low $1.48
Day low $1.75 Volume 20,900
Day high $1.80 Avg. volume 5,059
50-day MA $1.88 Dividend yield N/A
200-day MA $1.93 Market Cap 10.26M

IMRN Stock Price Chart Interactive Chart >

IMRN Stock Summary

  • Of note is the ratio of IMMURON LTD's sales and general administrative expense to its total operating expenses; 98.73% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for IMMURON LTD is higher than it is for about just 0.22% of US stocks.
  • As for revenue growth, note that IMRN's revenue has grown 955.47% over the past 12 months; that beats the revenue growth of 99.18% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to IMMURON LTD, a group of peers worth examining would be VJET, LODE, CYD, ALV, and WWD.
  • Visit IMRN's SEC page to see the company's official filings. To visit the company's web site, go to www.immuron.com.au.

Immuron Limited (IMRN) Company Bio


Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.


IMRN Latest News Stream


Event/Time News Detail
Loading, please wait...

IMRN Latest Social Stream


Loading social stream, please wait...

View Full IMRN Social Stream

Latest IMRN News From Around the Web

Below are the latest news stories about IMMURON LTD that investors may wish to consider to help them evaluate IMRN as an investment opportunity.

Immuron Clinical Trials Update

Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been completedPre-IND submission to the U.S. Food and Drug administration (FDA) planned for H1 2024 Travelan® clinical study inpatient phase completed and 6 month follow up visits planned MELBOURNE, Australia, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian base

Yahoo | December 22, 2023

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosisNew CampETEC product is a prophylactic therapeutic designed to protect against Campylobacter and Enterotoxigenic Escherichia coli (ETEC) infections, two of the major causes of Travelers’ diarrhea The in-patient stage of the study is anticipated to be

Yahoo | December 4, 2023

Immuron CEO, Steven Lydeamore Investor Webinar Presentation

MELBOURNE, Australia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar “Coffee Microcaps Morning Meeting”, to be held on Thursday, 30th of November, 2023, 9:00am ADEST. CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones. Following the presentation, attendees will have the opportunity to ask q

Yahoo | November 28, 2023

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military has commenced the second cohortThe clinical study 6 month follow up of Cohorts 1 and 2 anticipated to be completed in April 2024Travelan® is known to protect against the onset of Traveler’s diarrhea (TD), the most common illness reported by travelers MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limit

Yahoo | October 18, 2023

Immuron achieves record quarterly Travelan® sales

Highlights: Record quarterly Travelan® sales of $1,550,240Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales130% higher than pre-pandemic period Q1, FY20 sales MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplemen

Yahoo | October 11, 2023

Read More 'IMRN' Stories Here

IMRN Price Returns

1-mo -2.96%
3-mo -2.70%
6-mo -6.63%
1-year -10.45%
3-year N/A
5-year N/A
YTD -4.00%
2023 -9.86%
2022 -16.80%
2021 N/A
2020 N/A
2019 N/A

Continue Researching IMRN

Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:

Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!